Summary of reviewed studies (including results) involving role of proliferation and apoptosis in MDS, MDS/MPN, and AML
| Study . | BM malignancy (n) . | Proliferation marker (↑/↓) . | Apoptosis marker (↑/↓) . | Prognostic value . |
|---|---|---|---|---|
| Parker et al,29 2000 | MDS (67), AML (35) | — | Bax/Bad:Bcl-2/Bcl-x (↓) | Higher risk stratification |
| Matarraz et al,30 2012 | MDS (106) | DRAQ5 (↓) | — | Shorter survival, transformation to AML |
| Riccardi et al,67 1986 | AML (46) | PI staining (↑) | — | Shorter survival |
| Riccardi et al,68 1991 | AML (54) | BrdU staining (↑) | — | Complete remission, duration of remission |
| Brons et al,69 1993 | AML (33) | IdU staining (↑) | — | Longer 3-y survival, longer recurrence free survival |
| Alexandrakis et al,70 2004 | MDS (54) | Ki-67 (↑) | — | Higher risk of transformation |
| Alexandrakis et al,71 2005 | MDS (51) | PCNA (↑) | — | Higher risk of transformation |
| Allampallam et al,72 2002 | MDS (145) | IdU and BrdU (↓) | — | Higher risk of transformation |
| Davis et al,73 1998 | MDS (33) | — | Progression of MDS to AML | |
| Del Poeta et al,74 2003 | AML (255) | Bax:Bcl-2 (↓) | Shorter survival, disease-free survival, lower complete remission | |
| Mehta et al,75 2013 | AML (76) | — | Bcl-2 (↑) | Lower response to chemotherapy |
| Invernizzi et al,76 2004 | AML (98) | — | Survivin (↑) | Lower therapy response |
| Invernizzi et al,77 2006 | CMML (34) | — | Survivin (↑) | Shorter survival |
| Wagner et al,78 2006 | AML (74) | — | Survivin (↑) | Shorter survival |
| Gupta et al,79 1999 | MDS (50) | — | FasL (↑) | Shorter survival, transfusion dependency |
| Shimazaki et al,80 2000 | Control (10), MDS (51), AML (6) | — | DNA fragmentation (↑) | Shorter survival |
| Ohshima et al,81 2003 | Control (10), MDS (51), AML (6) | — | Caspase-3 (↑) | Shorter survival |
| Dereń-Wagemann and Kuliczkowski,82 2019 | AML (38) | — | Annexin V (↑) | Higher therapy response |
| Study . | BM malignancy (n) . | Proliferation marker (↑/↓) . | Apoptosis marker (↑/↓) . | Prognostic value . |
|---|---|---|---|---|
| Parker et al,29 2000 | MDS (67), AML (35) | — | Bax/Bad:Bcl-2/Bcl-x (↓) | Higher risk stratification |
| Matarraz et al,30 2012 | MDS (106) | DRAQ5 (↓) | — | Shorter survival, transformation to AML |
| Riccardi et al,67 1986 | AML (46) | PI staining (↑) | — | Shorter survival |
| Riccardi et al,68 1991 | AML (54) | BrdU staining (↑) | — | Complete remission, duration of remission |
| Brons et al,69 1993 | AML (33) | IdU staining (↑) | — | Longer 3-y survival, longer recurrence free survival |
| Alexandrakis et al,70 2004 | MDS (54) | Ki-67 (↑) | — | Higher risk of transformation |
| Alexandrakis et al,71 2005 | MDS (51) | PCNA (↑) | — | Higher risk of transformation |
| Allampallam et al,72 2002 | MDS (145) | IdU and BrdU (↓) | — | Higher risk of transformation |
| Davis et al,73 1998 | MDS (33) | — | Progression of MDS to AML | |
| Del Poeta et al,74 2003 | AML (255) | Bax:Bcl-2 (↓) | Shorter survival, disease-free survival, lower complete remission | |
| Mehta et al,75 2013 | AML (76) | — | Bcl-2 (↑) | Lower response to chemotherapy |
| Invernizzi et al,76 2004 | AML (98) | — | Survivin (↑) | Lower therapy response |
| Invernizzi et al,77 2006 | CMML (34) | — | Survivin (↑) | Shorter survival |
| Wagner et al,78 2006 | AML (74) | — | Survivin (↑) | Shorter survival |
| Gupta et al,79 1999 | MDS (50) | — | FasL (↑) | Shorter survival, transfusion dependency |
| Shimazaki et al,80 2000 | Control (10), MDS (51), AML (6) | — | DNA fragmentation (↑) | Shorter survival |
| Ohshima et al,81 2003 | Control (10), MDS (51), AML (6) | — | Caspase-3 (↑) | Shorter survival |
| Dereń-Wagemann and Kuliczkowski,82 2019 | AML (38) | — | Annexin V (↑) | Higher therapy response |
Direction of arrows (up or down) indicates whether patient group with higher or lower staining intensity, respectively, showed significantly different outcome (listed under final column).
CMML, chronic myelomonocytic leukemia.